Market Place
Sourcing Support
ANI Pharmaceuticals Initiates Alimera Sciences Acquisition
16 Sep 2024 //
GLOBENEWSWIRE
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
11 Sep 2024 //
GLOBENEWSWIRE
Ani Pharmaceuticals Updates On Alimera Sciences Acquisition
10 Sep 2024 //
GLOBENEWSWIRE
Alimera Sciences Reports Second Quarter 2024 Results
06 Aug 2024 //
GLOBENEWSWIRE
ANI Pharmaceuticals To Acquire Alimera Sciences
24 Jun 2024 //
CONTRACT PHARMA
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jun 2024 //
GLOBENEWSWIRE
Alimera Sciences Reports First Quarter 2024 Results
14 May 2024 //
GLOBENEWSWIRE
Alimera YUTIQ Data At ARVO And Retina World Congress Conferences
07 May 2024 //
GLOBENEWSWIRE
Alimera Sciences Q1 2024 Results on May 14, Corporate Update
30 Apr 2024 //
GLOBENEWSWIRE
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 2024 //
GLOBENEWSWIRE
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial
19 Mar 2024 //
GLOBENEWSWIRE
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
07 Mar 2024 //
GLOBENEWSWIRE
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Alimera Completes Recruitment for the Synchronicity Study
04 Jan 2024 //
GLOBENEWSWIRE
Alimera Sciences Names Elliot Maltz as Chief Financial Officer
02 Jan 2024 //
GLOBENEWSWIRE
Alimera Sciences Appoints Todd Wood as President of U.S. Operations
12 Dec 2023 //
GLOBENEWSWIRE
Alimera Appoints Maggie A. Pax to Its Board of Directors
08 Nov 2023 //
GLOBENEWSWIRE
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented
31 Oct 2023 //
GLOBENEWSWIRE
Alimera Sciences Reports Third Quarter 2023 Results
26 Oct 2023 //
GLOBENEWSWIRE
Alimera Sciences to Report Third Quarter 2023 Financial Results
16 Oct 2023 //
GLOBENEWSWIRE
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data
11 Oct 2023 //
GLOBENEWSWIRE
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
03 Oct 2023 //
GLOBENEWSWIRE
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Alimera Sciences Reports Second Quarter 2023 Results
10 Aug 2023 //
GLOBENEWSWIRE
Alimera Sciences to Report Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Alimera Completes Recruitment for its Landmark NEW DAY Study
24 May 2023 //
GLOBENEWSWIRE
Alimera Acquires U.S. Commercial Rights to YUTIQ®
18 May 2023 //
GLOBENEWSWIRE
Alimera to Host Rescheduled Update Call on Thursday, May 18, 2023, at 8:30am ET
17 May 2023 //
GLOBENEWSWIRE
Alimera Sciences Reports First Quarter 2023 Results
15 May 2023 //
GLOBENEWSWIRE
Alimera Sciences to Report 1Q 2023 FYR on May 15, 2023, and Corporate Update
08 May 2023 //
GLOBENEWSWIRE
Alimera Data to be Featured in Scientific Programming at Annual Congress
20 Apr 2023 //
GLOBENEWSWIRE
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma
03 Apr 2023 //
GLOBENEWSWIRE
Alimera Sciences Announces 2022 Financial Results and Business Update
31 Mar 2023 //
GLOBENEWSWIRE
Alimera Improves Capital Structure, Strengthens Balance Sheet
27 Mar 2023 //
GLOBENEWSWIRE
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
27 Feb 2023 //
GLOBENEWSWIRE
Alimera Announces Submission of MAA in Switzerland for ILUVIEN
22 Feb 2023 //
GLOBENEWSWIRE
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as CFO
09 Jan 2023 //
GLOBENEWSWIRE
Alimera Sciences Agreement to Extend Amortization Date and Interest-Only Period
08 Dec 2022 //
GLOBENEWSWIRE
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists
29 Nov 2022 //
GLOBENEWSWIRE
Alimera Sciences to Report Third Quarter 2022 Financial Results in November
02 Nov 2022 //
GLOBENEWSWIRE
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN®
01 Nov 2022 //
GLOBENEWSWIRE
Paladin Phase 4 Study Confirms ILUVIEN® Patients`
06 Oct 2022 //
GLOBENEWSWIRE
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf
23 Sep 2022 //
GLOBENEWSWIRE
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN®
20 Sep 2022 //
GLOBENEWSWIRE
Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data
31 Aug 2022 //
GLOBENEWSWIRE
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology VC
10 Aug 2022 //
GLOBENEWSWIRE
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN
09 Aug 2022 //
GLOBENEWSWIRE
Alimera Sciences Announces Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Alimera Announces Pricing and Reimbursement of Uveitis Granted for ILUVIEN
22 Jul 2022 //
GLOBENEWSWIRE
Alimera Sciences to Report Second Quarter 2022 Financial Results
22 Jul 2022 //
GLOBENEWSWIRE
Alimera Announces Approval and Pricing Granted for ILUVIEN for Uveitis in Italy
08 Jul 2022 //
GLOBENEWSWIRE
Alimera Sciences to Present at the LD Micro Invitational XII Conference
02 Jun 2022 //
GLOBENEWSWIRE
Phase 4 Study Confirms Positive Predictive Value of Corticosteroid Course
12 May 2022 //
GLOBENEWSWIRE
Alimera Sciences Reports First Quarter 2022 Results
09 May 2022 //
GLOBENEWSWIRE
Alimera Sciences to Report First Quarter 2022 Financial Results
06 May 2022 //
GLOBENEWSWIRE
Recent Alimera Data Featured in Scientific Programming
28 Apr 2022 //
GLOBENEWSWIRE
Alimera Exhibits Continued Growth and Expansion
06 Apr 2022 //
GLOBENEWSWIRE
Alimera Sciences to Present at the Q1 Investor Summit Conference
02 Mar 2022 //
GLOBENEWSWIRE
